Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells 2,366 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total value of $245,803.74. Following the transaction, the chief executive officer now owns 137,398 shares of the company’s stock, valued at approximately $14,274,278.22. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Grant Pickering also recently made the following trade(s):

• On Friday, November 1st, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $106.82, for a total value of $1,602,300.00.
• On Monday, October 7th, Grant Pickering sold 7,098 shares of Vaxcyte stock. The stock was sold at an average price of $109.21, for a total value of $775,172.58.
• On Friday, August 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00.

Vaxcyte Stock Up 3.9 %

Shares of Vaxcyte stock opened at $106.67 on Friday. The firm has a market cap of $13.30 billion, a price-to-earnings ratio of -23.19 and a beta of 1.01. The business has a fifty day simple moving average of $111.56 and a 200-day simple moving average of $87.23. Vaxcyte, Inc. has a fifty-two week low of $46.16 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the company earned ($0.91) EPS. Analysts anticipate that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds have recently modified their holdings of PCVX. Riverview Trust Co purchased a new stake in shares of Vaxcyte during the third quarter valued at $27,000. Fifth Third Bancorp purchased a new stake in shares of Vaxcyte during the second quarter valued at $35,000. Blue Trust Inc. lifted its holdings in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the last quarter. J.Safra Asset Management Corp lifted its holdings in shares of Vaxcyte by 649.4% during the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after purchasing an additional 526 shares during the last quarter. Finally, Quest Partners LLC purchased a new stake in shares of Vaxcyte during the second quarter valued at $70,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PCVX has been the subject of a number of analyst reports. Leerink Partners boosted their price target on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group boosted their price target on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Mizuho boosted their price target on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. BTIG Research boosted their price target on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte has a consensus rating of “Buy” and a consensus price target of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.